✦ LIBER ✦

PCV47 COST-EFFECTIVENESS OF FONDAPARINUX AND ENOXAPARIN IN PATIENTS WITH NON ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROME IN BRAZIL

✍ Scribed by C. Pepe; M. Machado; A. Olimpio; M. Canella; R. Ramos

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCV67 COST-EFFECTIVENESS OF FONDAPARINUX

✍ PA Vorobyev; O Borisenko; M Lesnicheva; S Shiganov; A Lomakin 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

PCV5 LONG-TERM COST-EFFECTIVENESS OF CLO

✍ B Brüggenjürgen; B Ehlken 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

Fondaparinux dominates enoxaparin sodium

📂 Article 📅 2007 🏛 Adis International Limited (now part of Wolters Kl ⚖ 124 KB

PCV1 COST-EFFECTIVENESS ANALYSIS OF CLOP

✍ K Borsos; B Nagy; J Spiesser; S Gabriel; G Blaskó 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

Fondaparinux compared to enoxaparin in p

✍ Campbell D. Joyner; Ron J.G. Peters; Rizwan Afzal; Susan Chrolavicius; Shamir R. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 266 KB

PCV4 Comparative Effectiveness Research

✍ Romyen, C.; Chaiyakunapruk, N.; Permsuwan, U. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB